Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Guilhufe – page 22

694 clinical trials in Guilhufe, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Guilhufe at a glance
694
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

694 trials in Guilhufe

Open in trial search

Bronchiectasis

Not yet recruiting

Efficacy and safety of galvokimig in adults with non‑cystic fibrosis bronchiectasis: a randomized, double‑blind, placebo‑controlled phase 2 trial

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Agomab Spain S.L.

Conjunctivitis allergic+1

Not yet recruiting

Efficacy and safety of Depigoid Olea 1000 DPP/ml compared with placebo in patients with moderate to severe allergic rhinoconjunctivitis due to olive pollen

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:LETI Pharma S.L.U.

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Celea Therapeutics Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Guilhufe

What the registry says about research in the country

01 Autoimmune Disorders

Innovative research focusing on Systemic Lupus Erythematosus (SLE) treatment evaluation, examining new therapeutic approaches for patients with moderate to severe manifestations of the disease.

  • Disease management strategies
  • Long-term safety assessment
  • Treatment efficacy evaluation

Studies aim to advance understanding of treatment responses in adults with active SLE despite ongoing therapy.

02 Cardiovascular Medicine

Advanced clinical research investigating stroke prevention in patients with atrial fibrillation, comparing innovative anticoagulation approaches.

  • Stroke prevention strategies
  • Bleeding risk assessment
  • Systemic embolism prevention

Comparative studies evaluating treatment efficacy and safety profiles in cardiac patients.

03 Infectious Diseases

Observational research examining mpox virus disease outcomes and treatment effectiveness, with particular focus on antiviral interventions.

  • Clinical outcome analysis
  • Antiviral treatment evaluation
  • Disease progression monitoring

Research aims to enhance understanding of treatment responses in infected patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.